U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    111.09
    +2.66 (+2.45%)
     
  • Gold

    1,810.50
    +9.00 (+0.50%)
     
  • Silver

    20.01
    +0.35 (+1.77%)
     
  • EUR/USD

    1.0431
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2108
    +0.0004 (+0.03%)
     
  • USD/JPY

    136.1810
    +0.5210 (+0.38%)
     
  • BTC-USD

    20,289.65
    +1,117.46 (+5.83%)
     
  • CMC Crypto 200

    439.87
    +19.73 (+4.70%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • Nikkei 225

    26,433.66
    +279.85 (+1.07%)
     

Wellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas Event

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Wellbeing Digital Sciences Inc.
Wellbeing Digital Sciences Inc.

Dr. Hilmas will Represent the Company at the IPA World Congress and Probiota Americas Event Organized by William Reed Ltd. and Taking Place from June 1-3, 2022, Where he is will Comment on Key Concerns, Advances and Understandings Surrounding the Latest Developments in Prebiotics and Probiotics

VANCOUVER, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research is pleased to announce that Dr. Corey Hilmas MD, PhD, a member of the Company’s Medical Advisory Board, will be participating as part of a regulatory panel (the “Panel”) at the 2022 IPA World Congress and Probiota Americas Event (“Probiota Americas” or the “Event”).

The Event will be held in Washington D.C. from June 1-3, 2022 and the panelists are expected to discuss the pressing issues in the probiotics field regarding labelling, ensuring safe usage, expanding health indications for probiotics and New Dietary Ingredient (“NDI”) notifications.1 The Panel has been announced as consisting of four subject matter experts including Dr. Hilmas; Solange Henoud, Vice President Regulatory and Compliance at Lallemand Health Solutions Inc.; Serna Viswanathan, JD, of the Federal Trade Commission; and Betsy Jean Yakes, PhD, of the Food and Drug Administration.1 The Panel will begin with short presentations and be followed by an open discussion.

Dr. Hilmas also currently serves as the Chief Regulatory Officer of the Company’s wholly owned subsidiary, KGK Science Inc. (“KGK”). He is a respected scientist, medical doctor, and former federal food regulator in the United States (“US”). After having completed his medical degree and a doctorate in toxicology, working as a principal investigator for many years, and serving on behalf of the US government at the Food and Drug Administration (“FDA”), Dr. Hilmas combines his unique medical and scientific skillset with extensive US regulatory training. He served as an NDI notification reviewer and as a branch chief within the Division of Dietary Supplement Programs at the FDA. In addition to working on enforcement matters related to supplement labelling, claims, good manufacturing practices and fraud, he also served as an expert witness for the FDA and Department of Justice, resulting in an FDA Award of Merit from former FDA Commissioner Margaret Hamburg.

IPA World Congress and Probiota Americas, a collaborative annual event that is considered the leading occurrence for prebiotic, probiotic and the microbiota-focused food and pharmaceutical industries, is scheduled to be held at the Crystal Gateway Marriott Hotel in Washington, DC. The Event is offered by Nutraingredients-USA.com, also known as William Reed Ltd., a media, business intelligence and events group dedicated to helping businesses succeed. Probiota Americas features world-leading experts who present the latest scientific, technical, and market insights in the industry, and provides networking opportunities for individuals and companies alike. The Event also includes the Scientific Frontiers, Probiota Pioneers and Wellness Program sessions during the weekend.2 More information about the Event can be found on its website: https://probiotaamericas.com/live/en/page/home.

Management Commentary

“We are pleased that Dr. Hilmas has been invited to speak on the Panel at the Probiota Americas event,” said Najla Guthrie, CEO of Wellbeing. “Aside from his day-to-day role at KGK, he has enriched the Company’s Medical Advisory Board and I believe that he will add great value to the Panel and Event as well. We also excited for Dr. Hilmas to bring new information back to the Company after the Event. An event like Probiota America is important to our industry as it focuses on the wellbeing of consumers, which aligns well with our goals and beliefs,” added Ms. Guthrie.

RSU Grant

The Company also announces that its Board of Directors has approved a grant of 1,260,000 restricted share units (the "RSUs") in aggregate to an affiliate of an arm’s length consultant, pursuant to the Company's RSU plan. The RSUs vested immediately on the date of issuance and each RSU entitles the holder to receive one common share of the Company in exchange.

ABOUT KGK SCIENCE

Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. The business has successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. In essence, the Company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

"Najla Guthrie"
Najla Guthrie, Chief Executive Officer

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co
Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR

Kirsten Krose, President
SWON Public Affairs
Tel: 613-558-9210
Email: Kirsten@swonpublicaffairs.com

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

ENDNOTES

  1. “Probiota Americas panel to delve into NDI guidance, labeling, additional issues”, by Hank Schultz, NURTAingredients-USA.com, May 19, 2022, https://www.nutraingredients-usa.com/Article/2022/05/19/probiota-americas-panel-to-delve-into-ndi-guidance-labeling-additional-issues

  2. “Probiota Americas 2022”, Probiota Americas, 2022, https://probiotaamericas.com/live/en/page/home